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Safety of a nano-sized UV filter in a 
multifunctional product
Introduction
Several excipients have to be used in cosmetic emulsions to reach the desired
product requirements, e.g. physicochemical stability, a satisfactory safety profile
and sensorial properties, including surfactants, preservatives and emollients. It is
of crucial importance to evaluate the safety profile of the ingredients used in such
vehicles.
As imposed by legislation, cosmetic emulsions, in their intended use, must be safe
for the consumer. In Europe, they fall under the general requirements of the
Regulation (EC) Nº 1223/2009. Under this regulation, the toxicological profile of all
ingredients and detailed product-specific exposure knowledge are fundamental for
the safety assessment. The safety of a cosmetic product is determined based on
the safety assessment of its ingredients through literature data, in vitro tests and in
vivo tests in humans. Some ingredients are of special concern, e.g. preservatives
and UV filters, especially those used in nano-sized form.
Methods
The safety assessment was performed according to the Scientific Committee on
Consumer Safety (SCCS) guidance [1].
Hazard identification: The results of the in vitro and in vivo tests, clinical studies,
physical, chemical and toxicological properties of each ingredient were considered
to recognize if the ingredient has the potential to damage human health.
Dose-response assessment: The dose-response assessment describes the
change in effect on an organism caused by differing levels of exposure to a
chemical after a certain time of exposure. In the case of an effect with a threshold,
the dosage at which there is ‘No Observed Adverse Effect Level’ (NOAEL) is
determined.
Exposure assessment: The amount and the frequency of human exposure to the
MBBT-loaded emulsions were determined using the systemic exposure dose
(SED) that was calculated for each ingredient, according to Equation 1.
Equation 1:
Where, E is the amount expected to enter the blood stream per kg body weight
per day, C is the concentration of the ingredient in the MBBT-loaded emulsions
and DA is the dermal absorption reported as a percentage of the test dose
expected to be applied under conditions simulating those of real-life.
Risk characterization: The probability that the substances under study cause
damage to human health was considered. In the case of a threshold effect, the
margin of safety (MoS) was calculated according to the Equation 2.
Equation 2:
A safety evaluation study, using the Marzully and Maibach [2] Human Repeat
Insult Patch Test (HRIPT) was performed for the MBBT-loaded emulsions to
evaluate the product’s irritant and allergic capacity in 51 volunteers. A protocol
identical to the one previously described by Marto et al was followed [3]. This
protocol was approved by the local Ethical Committee and respected the Helsinki
Declaration and the AFSSAPS regulations on performed HRIPT studies on
cosmetic products. The study was conducted under the supervision of a
dermatologist.
Given the high lipophilicity of MBBT, attention should be given to its identification
in selected tissues to obtain information on potential bioaccumulation. MBBT’s use
as a sunscreen ingredient might lead to environmental exposure. The SCCS
noted that, due to poor biodegradation potential and high partition coefficient, long
term effects in the environment cannot be excluded; MBBT is currently classified
with R 53/Chronic 4 – ‘may cause long term effects on the aquatic environment’.
For the intended use, the evaluation of available data on MBBT does not indicate
a significant risk that outweighs its benefits.
Furthermore, clinical data, albeit largely gathered by pilot investigations, indicates
very low incidence of adverse events; together with the HRIPT results it can be
concluded that this product shows very good skin compatibility.
Discussion & Conclusion
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Results
Aim
The aim of this study was to evaluate the safety profile and biological effects of a
newly developed cosmetic emulsion containing Methylene Bis-Benzotriazolyl
Tetramethylbutylphenol (MBBT) (Tinosorb ® M, obtained from BASF, S.E.) as an
Ultraviolet (UV) filter, using literature data and a systematic approach for the
safety assessment, comparing it with in vitro and in vivo data obtained by methods
of skin bioengineering and tests on human volunteers, respectively.
MBBT is composed of 50.0% organic micro-fine particles, with a particle size
below 200 nm; thus this ingredient is considered to be nano-sized.
The assessment of the safety for human health of the finished product took into
consideration the toxicological profile of each ingredient, their chemical structures
and their exposure levels.
The MBBT-loaded emulsion did not induce any irritant (induction phase) or allergic
reactions (challenge phase) in occlusive-patch tests.
Despite the high values obtained for MBBT, it should be taken in account that this
ingredient has a particle size below 200 nm. The Scientific Committee on
Consumer Safety issued and opinion considering this ingredient in 2013 [4].
Nevertheless, attention needs to be paid to the identification/presence in selected
tissues to obtain information on potential bioaccumulation given the physical and
chemical properties (namely lipophilicity) of the substance.
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Table 1. Summary of the safety data of Tinosorb® M. 
Table 2. Results for the Human Repeat Insult Patch Test (HRIPT).
INCI Acute toxicity Dermal toxicity SED* MoS**
Methylene Bis-
Benzotriazolyl
Tetramethylbutylphenol
(and) Aqua (and) Decyl
Glucoside (and) 
Propylene Glycol (and) 
Xanthan Gum
LD50 (oral) rat > 
2000 mg/L
LD50 (dermal) rat 
> 5000 mg/kg
0.724 1381.22
*C = 0.3%; **NOAEL = 1000 [4].
Induction phase
Type of reactivity on the 
induction site
Number and percentage of 
reactive volunteers
0 0/0%
Challenge phase
Type of reactivity on the 
induction site and virgin site
Number and percentage of 
reactive volunteers
0 0/0%
